Indian Chemical News, an online news media covering Pharma, Chemical and Petrochemical sector is organizing an E-conference on “India's Pharma Industry Outlook 2021” on 12th February, 2021 from 3:00 PM – 4:30 PM.

The speakers for the E-conference speakers are: Yogin Majmudar, CMD, Bakul Group; Raghuveer Kini, Former ED, PHARMEXCIL; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR - IICT; Narayanan Suresh, COO, ABLE; Govind Jaju, Partner, Suingora Consulting; Abhinav Dhandia, CEO, Sphaera Pharma; Sameer Rawal, Founder Director, Magnizent Pharma-Chem; Srini Konduru, VP – Consulting & Business Development, BioQuest Solutions; and Pravin Prashant, Editor, Indian Chemical News.

India’s domestic pharmaceutical market turnover reached US $20.03 billion in 2019, up 9.8% year on year from US $18.12 billion in 2018. Pharmaceutical exports, including bulk drugs, intermediates, drug formulations, biologicals, Ayush & herbal products and surgical, reached US $16.28 billion in FY20.

India supplies over 50% of the global demand for various vaccines, 40% of the generic demand for the United States and 25% of all medicines for the United Kingdom. Indian drugs are exported to more than 200 countries with the US being the key market. Generic drugs account for 20% of the global export in terms of volume, making the country the largest provider of generic medicines globally.

Speaking about the Indian Pharma Industry Outlook 2021, Pravin Prashant, Editor, Indian Chemical News said, "India should focus on building its own capacities even for Intermediates and APIs so that our dependence on China reduces. This will help in bringing a lot of investment and also create a lot of employment opportunities in the country."         

‘Pharma Vision 2020’ by the Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery. The sector received cumulative Foreign Direct Investment (FDI) worth US $16.54 billion between April 2000 and June 2020. India plans to set up a nearly Rs. 1 lakh crore (US $1.3 billion) fund to provide a boost to companies to manufacture pharmaceutical ingredients domestically by 2023.

The key discussion points for the pharma E-conference are: Pharma industry global and India outlook in 2021; Redefining India's Pharma target for 2021; Role of COVID-19 Vaccine in India's growth story; Identifying growth drivers across key Pharma segments in 2021; - Manufacturing pharmaceutical ingredients domestically by 2023; Opportunities generated through Production Linked Incentive (PLI) Scheme in 2021; R&D push for novel molecules: Academia and Industry Collaboration; and Access to next generation technologies across value chain.

Here's the link to pre-register for attending the live session on 12th February 2021 from 3:00 PM to 4:30 PM IST